What causes premenstrual water retention?

Premenstrual Water Retention: Causes

Premenstrual water retention is caused by disturbed fluid distribution and hormonal dysregulation during the late luteal phase, specifically involving decreased atrial natriuretic factor (ANF), increased arginine vasopressin (AVP) sensitivity with a lower threshold for release, elevated renin-aldosterone activity, and reduced renal prostaglandin excretion—not actual total body water accumulation. 1, 2

Hormonal Mechanisms

The pathophysiology centers on multiple interrelated hormonal disturbances that occur specifically during the late luteal menstrual phase:

Vasopressin (AVP) Dysregulation

• Women with PMS have a significantly lower threshold for AVP release and increased AVP sensitivity (amount secreted per unit rise in plasma osmolality) during the luteal phase 2
• AVP levels paradoxically remain lower throughout the menstrual cycle in symptomatic PMS patients compared to controls, suggesting a chronic neurobiological vulnerability 3
• The lower AVP threshold promotes fluid retention even at lower plasma osmolality levels 2

Atrial Natriuretic Factor (ANF) Deficiency

• Plasma ANF levels are significantly lower during the luteal phase in women with PMS, representing a relative deficiency of this natriuretic hormone 2
• Lower basal ANF levels persist even with saline loading, indicating impaired compensatory mechanisms 2
• This ANF deficiency fails to counterbalance the fluid-retaining effects of other hormones 2

Renin-Aldosterone System Activation

• During the late luteal phase, women with PMS demonstrate significantly elevated plasma renin activity (PRA) and aldosterone levels compared to controls 1
• Upright PRA reaches 3.9±0.08 versus 1.6±0.3 ng/mL/hour in controls (p=0.015), and upright aldosterone reaches 208±40 versus 102±16 pg/mL in controls (p=0.03) 1
• This activation promotes sodium and water retention through renal mechanisms 1

Prostaglandin Reduction

• Urinary excretion of prostaglandin E2 and prostaglandin F2α is significantly reduced in women with PMS during the luteal phase 4
• Cyclic adenosine monophosphate (cAMP) excretion is also decreased, indicating altered renal handling of water and electrolytes 4
• This reduction impairs the kidney's ability to excrete sodium and water appropriately 4

Fluid Distribution Rather Than Retention

The key pathophysiological insight is that PMS involves fluid redistribution rather than true water retention:

• Women with PMS show a significantly lower maximal plasma volume shift during orthostatic challenge (11.7±1.3 versus 15.6±0.6 in controls; p=0.004) during the late luteal phase 1
• The area under the curve for total plasma shift over 30 minutes of standing is reduced (300±28 versus 406±16; p=0.01) 1
• Despite ankle edema being present in PMS patients during late luteal phase, no change in total body weight occurs 1, 5

Transcapillary Fluid Balance Alterations

• Interstitial colloid osmotic pressure on the leg decreases significantly (mean 3.6 mm Hg reduction; p=0.005) from follicular to luteal phase 5
• Capillary filtration coefficient increases 30% (mean 5.3 x 10⁻⁴ ml/min/100 gm/mm Hg; p=0.04) during the luteal phase 5
• These changes indicate vascular instability and fluid shift from intravascular to interstitial compartments, particularly in dependent areas 5

Clinical Implications

Mechanism Summary

The bloating and edema symptoms result from:

• Fluid shifting from the vascular compartment into interstitial tissues (especially lower extremities) due to increased capillary permeability 5
• Impaired compensatory natriuretic mechanisms (low ANF) 2
• Enhanced fluid retention signals (high renin-aldosterone, altered AVP threshold) 1, 2
• Reduced renal prostaglandin-mediated diuresis 4

Therapeutic Rationale

Progesterone therapy can reverse some of these abnormalities by stimulating ANF release, inhibiting AVP release/synthesis, and increasing the AVP threshold 2. This explains why progesterone may provide symptomatic improvement beyond its direct hormonal effects 2.